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The human neuronal nitric oxide synthase (NOS1) gene is subject to extensive splicing. A total of 12 NOS1 mRNA species have been
identified. They differ in their 5′ ends and are derived from 12 different first exons (termed exons 1a to 1l). Various cell lines whose NOS1 first
exon expression patterns were representative of human brain, skin, and skeletal muscle were identified. These included A673 neuroepithelioma
cells, SK-N-MC neuroblastoma cells, HaCaT keratinocyte-like cells, and C2C12 myocyte-like cells. In these cell lines, correlations were found
between the exon 1 variants preferentially expressed and the promoter activities of their cognate 5′ flanking sequences. These data demonstrate
that expression of the different exon 1-related splice variants of NOS1 mRNA is controlled directly (at least in part) by the associated 5′ flanking
sequences.
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to express neuronal-type nitric oxide synthase (NOS1) [1]. In
brain, nitric oxide (NO) produced by NOS1 is known to
function as a modulator of neuronal function affecting the
release of neurotransmitters and playing a role in long-term
potentiation as well as in long-term depression [2]. In peripheral
tissues, numerous other functions have been attributed to NOS1,
such as modification of skeletal muscle contractile force or
control of total body Na+ [3]. In addition, various conditions
have been described in which concentrations of NO rapidly
increase (e.g., ischemia–reperfusion injury or glutamate-
mediated neurodegenerative processes in the CNS). The
molecular mechanisms involved in these disorders include
both hyperactivation of the NOS1 enzyme and upregulated
expression of the NOS1 gene [4]. Structural mRNA diversity is
a hallmark of NOS1 expression and expressional regulation
seems unusually complex [5,6]. In addition to cell-specific⁎ Corresponding author. Fax: +49 6131 393 6588.
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doi:10.1016/j.ygeno.2005.11.013NOS1 mRNA splicing, we have previously found stimulus-
dependent switches in the predominant NOS1mRNA expressed
in a given cell [7].
Given the relevance of NOS1 in both physiology and
pathophysiology, and the important consequences of altered
expression, a profound understanding of the regulatory network
appears to be critical. Therefore, the current study was
undertaken to investigate the mechanisms controlling the
expression of the various NOS1 splice forms in different cell
types. We generated numerous reporter gene constructs to test
the potential function of exon 1-associated 5′ flanking
sequences for the transcription of the different NOS1 splice
variants.
Results
Cell-type-specific expression of human NOS1 exon 1 variants
We have recently demonstrated transcriptional usage of 10
different NOS1 exon 1 variants, expressed in a cell-type- and
464 M. Bros et al. / Genomics 87 (2006) 463–473stimulus-dependent manner in various human tissues [6]. In this
study, we have applied reverse transcriptase (RT) real-time PCR
analysis to quantify the relative expression levels of the various
exon 1 variants in human tissues.
As depicted in Fig. 1, human cerebral cortex and
hippocampus showed comparable expression patterns charac-
terized by a predominant usage of exons 1d, 1f, and 1g. In
cerebral cortex, NOS1 messages containing one of these exons
were expressed at comparable transcriptional levels (20–30%),
in hippocampus about half of all NOS1 transcripts contained
exon 1d. In both brain regions, exon 1k-containing NOS1Fig. 1. Expression of NOS1 mRNA splice variants in biopsies of human tissues. Tran
was assessed using RT real-time PCR. Sequences of the first exon-specific sense prime
exon 2-specific TaqMan probe are indicated in Table 1 and under Materials and Meth
tibialis muscle, heart, ileum, skin, kidney, testis. Two additional first exons (1c) and (1
indicated, but were not investigated because classical PCR failed to amplify spec
independent RNA preparations; +, transcripts detected, but representing less than 0.mRNAwas significantly less abundant (below 10%). In cerebral
cortex, we also found a low level of expression of exons 1b and
1l (“one ell”) (6 and 11%, respectively). In skin, other exon 1
variants were expressed at significant levels: exons 1d (40%),
1b (25%), and 1f (18%) accounted for the majority of the NOS1
transcripts, minor transcripts contained exon 1g (10%) and exon
1j (7%) (Fig. 1). In heart, the dominant NOS1 transcripts
contained either exon 1d or exon 1g (29 and 39%, respectively).
In addition, exon 1k was detected in about 15% of the NOS1
mRNA. Exons 1b, 1f, and 1l were expressed at lower levels,
each accounting for less than 10% of the total. In contrast, inscriptional diversity of NOS1mRNA expression (the use of different first exons)
rs (to exons 1a to 1l), of the common exon 2-specific antisense primer, and of the
ods. The following human tissues were analyzed: cerebral cortex, hippocampus,
h) reported by Wang et al. [5], but not detected by us in a previous study [6], are
ific 1c and 1h fragments (not shown). Data represent means ± SEM of three
2% of the total NOS1 mRNA.
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exon 1d. All other transcripts accounted for less than 5% of the
total NOS1 mRNA (Fig. 1). In testis, the majority of NOS1
transcripts contained exon 1g (50%), exon 1k (33%), or exon 1f
(21%). Exon 1a accounted for about 9% of total NOS1 mRNA
(Fig. 1). In ileum, NOS1 mRNA contained predominantly exon
1f (50%) or exon 1d (35%); exons 1g and 1k accounted for less
than 10% of total NOS1 mRNA (data not shown). In kidney,
quantitative PCR confirmed our previous finding of almost
exclusive usage of exon 1d (96%). Trace amounts of NOS1
transcripts harboring exons 1f, 1g, and 1k were also found (data
not shown).
Thus, in many cases exons 1d, 1f, and 1g were expressed
in parallel and accounted for the majority of NOS1 transcripts.
Exon 1k was expressed in all tissues analyzed, albeit at
varying levels. We have shown recently that exon 1k is often
spliced in between another exon 1 located more upstream in
the NOS1 gene and the common exon 2 [6]. Also in the
current study, we found exon 1k inserted between exon 1g
and exon 2 in cerebral cortex (20% of exon 1g-containing
NOS1 mRNA) and in skin (65% of exon 1g-containing NOS1
mRNA, data not shown).
Promoter test constructs for the multiple NOS1 exon 1 variants
To examine whether the transcription of the numerous NOS1
exon 1 variants was regulated by promoter activity of the
respective upstream flanking genomic regions, we used over-
lapping PAC clones spanning the genomic region of the human
NOS1 gene (Fig. 2A) to generate corresponding promoter
reporter constructs for each exon 1 variant. As depicted in Fig.
2B, these reporter constructs covered several kilobases of
genomic sequence for most exons to ensure that all relevant cis-
acting elements were covered. An additional set of truncated
reporter constructs spanning the putative core promoter regions
was also generated to exclude the possibility of promoter
interference (Fig. 2B).
NOS1 exon 1 expression pattern in NOS1-expressing cell lines
Given the importance of NOS1-derived NO for brain
function and its role in neurodegenerative diseases, we tested
the NOS1 promoter constructs in the neuroepithelioma cell line
A673 and the neuroblastoma cell line SK-N-MC (Fig. 3). Both
cell types express significant levels of NOS1 [6,7]. Due to the
relevance of NOS1 for skin proliferation and wound healing, we
included the NOS1-expressing keratinocytic cell line HaCaT in
our studies [8] (Fig. 3). Considering the role of NOS1 in skeletal
muscle function and its potential involvement in muscular
dystrophy, we aimed at testing the NOS1 promoter constructs in
a respective cell line. However, there is no NOS1-expressing
human skeletal muscle cell line. Therefore, these experiments
were performed in the NOS1-expressing murine myoblast cell
line C2C12 [9] (Fig. 3).
Quantitative PCR analyses revealed a similar NOS1 exon 1
expression pattern in A673 cells and SK-N-MC cells charac-
terized by a predominant usage of exons 1f, 1g, and 1k (Fig. 3,left). Whereas in A673 cells exon 1g accounted for 50% of
NOS1 transcripts and the adjacent exon 1f for an additional 29%
of NOS1 mRNA, the ratio was reversed in SK-N-MC cells.
Here exon 1f was present in 51% of NOS1 transcripts and exon
1g found in 20% of the NOS1mRNA (Fig. 3, left). Exon 1k was
expressed at the same level in either cell line (about 20% of all
NOS1 transcripts, Fig. 3, left). Thus, with the exception of
underrepresented exon 1d, the overall NOS1 expression patterns
in A673- and SK-N-MC cells were similar to those observed in
brain tissue (see Fig. 1).
In the human keratinocytic cell line HaCaT, exon 1g-
containing NOS1 transcripts were the dominant mRNA species
(59%); exons 1f and 1i were expressed at somewhat lower
levels (around 25% each), followed by exon 1k (about 15%). So
far, the expression pattern is similar to the NOS1 exon 1 pattern
found in skin (see Fig. 1). However, exons 1b and 1d, which
contributed to NOS1 expression in skin (Fig. 1), were not found
expressed in HaCaT cells.
Promoter function of NOS1 exon 1 5′ flanking genomic regions
in representative cell lines
As suggested by the high abundance of exon 1g-
containing NOS1 transcripts in A673 cells (Fig. 3, left), the
exon 1g full-length promoter test construct was 7.5-fold as
active as the promoterless pGL3-Basic vector. Interestingly,
the activity of the core promoter region of exon 1g was even
32-fold that of pGL3-Basic (Fig. 3, right). Despite the high
expression of exon 1f in A673 cells, the corresponding full-
length promoter showed only 2-fold activity over pGL3-
Basic, the truncated construct was four times more active
than pGL3-Basic. This suggests that the expression of exons
1f and 1g may be negatively regulated by more distant cis-
acting elements. In accordance with the significant expression
of exon 1k-containing NOS1 transcripts in A673 cells, the
full-length promoter of exon 1k showed significant activity
(14-fold that of pGL3-Basic). The marginal activity of the
corresponding deletion construct indicated that expression of
exon 1k relied essentially on cis-acting elements located
upstream of the exon 1j sequence region (which were deleted
in the truncated construct, see Fig. 2B). Corresponding to the
low expression levels of exons 1b, 1c, 1d 1e, 1i, 1j, and 1l in
A673 cells (Fig. 3, left), the respective reporter gene
constructs displayed low-to-moderate activity compared
with pGL3-Basic (Fig. 3, right).
Surprisingly, the full-length promoter construct for exon 1a,
which was barely expressed in A673 cells, showed substantial
promoter activity (17-fold over pGL3-Basic). The even greater
reporter gene activity (138-fold over pGL3-Basic) for the
respective truncated core promoter construct suggests that
transcriptional expression of exon 1a is negatively regulated by
a cis-acting region located in the 5′ part of the promoter region.
It is not clear why the exon 1a-related promoter activity does not
result in expression of exon 1a in A673 cells (Fig. 3, left). It is
possible that the repressive potential of the 5′ part of the
promoter region may be stronger in intact cells than detected by
transient promoter analysis.
Fig. 2. Organization of the 5′ end of the human NOS1 gene and schematic representation of the putative promoter-luciferase test constructs pertaining to the different
first exons of NOS1. (A) Schematic representation of the 5′ end of the human NOS1 gene showing the localization of the 12 distinct first exons (1a to 1l) and of exon 2
(boxes). The position of the translation start codon (ATG) on exon 2 is indicated. Relevant restriction sites used during the initial cloning steps (cloning of PAC clone
fragments into plasmid pZero-2.1) are indicated above the horizontal line representing the genomic DNA sequence. Restriction sites used for subcloning of putative
promoter sequences into the Photinus luciferase-containing vector pGL3-Basic are shown below the horizontal line. A, Acc65I; Ac, AccI; Ap, ApaLI; B, BamHI; Bs,
BsaI; Bt, BstAPI; E, EcoRI; Ea, EagI; Ec, Ecl136II; F, FspI; N, NheI; P, PstI; S, SmaI; Sc, ScaI; St, StuI; X, XbaI. The arrow under exon 1l indicates the specific
antisense primer used for the cloning of the corresponding promoter construct. (B) Scheme of the 5′ flanking regions of the different first exons of human NOS1 (exons
1a to 1l) and 5′–3′-deletion constructs thereof (NOS1 minimal promoter constructs). Proximal 5′ sequences of each first exon 1 were further subcloned in front of the
luciferase expression cassette (luc+). Construct names refer to the respective exon 1 sequence and to the length of the remaining 5′ flanking genomic sequence (in kb).
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expression pattern in the neuroblastoma cell line SK-N-MC
cells (Fig. 3, left), the full-length promoter constructs belonging
to exons 1f and 1g displayed the highest activity (9.5- and 8-foldFig. 3. Comparison of the expression of the different exon 1-derived splice forms of N
gene constructs (Fig. 2B) transfected into the same cells. Left: Quantitative analyses
SK-N-MC neuroblastoma cells, and human keratinocyte-like HaCaTcells. RT real-tim
transcripts detected, but representing less than 0.2% of the total NOS1 mRNA. Righ
exons of human NOS1 (exons 1a to 1l). The human cell lines A673, SK-N-MC, and
with one of the various NOS1 gene promoter constructs and a Renilla luciferase cor
experiments performed in duplicate. Normalized Photinus luciferase activities are gi
white bar and the horizontal line. Activities of the larger promoter fragments are ind
(see Fig. 2B for details).over pGL3-Basic, respectively). In contrast to A673 cells, the
truncated promoter region of exon 1f exerted reporter activity
similar to that of the full-length sequence, whereas the 5′
flanking region of exon 1g showed reduced activity relative toOS1mRNA in human cell lines with the activities of the NOS1 promoter reporter
of NOS1 mRNA splice variants in human A673 neuroepithelioma cells, human
e PCR of the different first exon-derived mRNAs was performed as for Fig. 1; +,
t: Analyses of promoter activities of the 5′ flanking regions of the different first
HaCaT, as well as the murine myoblast cell line C2C12, transiently transfected
eporter, were assayed 24 h later. Data represent means ± SEM of at least three
ven as fold of the promoterless vector control pGL3-Basic (B), indicated by the
icated by black bars, those of the derived 5′–3′-deletion constructs by gray bars
467M. Bros et al. / Genomics 87 (2006) 463–473the full-length construct (2.5-fold over pGL3-Basic). The
expression of exon 1k in SK-N-MC cells (Fig. 3, left) was
paralleled by reporter activity of the respective full-length
construct 5-fold over pGL3-Basic. In contrast, the truncated
construct had no promoter activity. The low or absent expressionof all other exon 1 species in SK-N-MC cells corresponded to
the low or absent activity of the respective promoter constructs
(Fig. 3, right). As observed in A673 cells, in SK-N-MC cells, the
reporter constructs of nonexpressed exon 1a displayed substan-
tial activity (4.5- and 20.5-fold, respectively).
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levels of adjacent exons 1f and 1g were reflected by the
activities of the respective full-length promoter constructs (7-
and 17-fold over pGL3-Basic). Interestingly, both truncated
constructs showed a marked decrease in activity (down to 2-
and 3.5-fold over pGL3-Basic, respectively). This is suggestive
of a cell-type-specific enhancer function due to cis-acting
regions located upstream of either core promoter. In agreement
with the endogenous expression state, the full-length promoter
of exon 1k was moderately active (6.2-fold over pGL3-Basic),
while the respective deletion construct lacked promoter activity.
In contrast to its substantial expression level, the exon 1i-Fig. 4. Scheme of potential transcription factor binding sites within the 5′–3′ trunc
indicated by gray boxes. If the construct contained an additional exon located upstr
identified by MatInspector v2.2 [34] and are indicated by black boxes and labeled. Fo
proximal 500 bp have been indicated.associated full-length promoter construct showed only 2.3-fold
the activity of pGL3-Basic, and the corresponding core
promoter had very little activity. In accordance with the low
or absent expression of exons 1b, 1c, 1d, 1e, 1j, and 1l in HaCaT
cells (Fig. 3, left), the corresponding reporter construct showed
very little or no activity (Fig. 3, right). As observed in the brain-
derived cell lines, the reporter constructs of exon 1a showed
high activity (12- and 27-fold over pGL3-Basic, respectively;
Fig. 3, right), although exon 1a is only a minor transcript in
HaCaT cells (Fig. 3, left).
In human skeletal muscle (and also in heart), there was a
marked expression of exon 1d (Fig. 1). Accordingly, in C2C12ated constructs of the various NOS1 promoters. Included exonic sequences are
eam it is indicated accordingly. Potential transcription factor binding sites were
r the longer promoter reporter constructs, only potential binding sites within the
Fig. 5. (A) Scheme of the genomic region of the NOS1 gene harboring exons 1f
and 1g (top). Shown below are reporter constructs containing the 5′ flanking
regions of exons 1f and 1g of human NOS1 and 5′–3′-deletion constructs
thereof. A conserved CRE binding site of potential functional importance (see
B) is indicated. (B) Effect of dibutyryl-cAMP on the activity of the human NOS1
promoter related to exons 1f and 1g. Activities of the full-length (black columns)
and truncated (gray columns) promoter reporter constructs associated with exons
1f and 1g were assessed in the neuroblastoma cell line SK-N-MC. Activities
were determined under basal conditions (solid columns) and following
stimulation with dibutyryl-cAMP (300 μM for 12 h, hatched columns).
Normalized Photinus luciferase activities are given as fold of basal activity of
the parental exon 1f promoter reporter construct (Pex1f-6.53). The promoterless
pGL3-Basic (B) was included as a negative control. Values represent
means ± SEM of three or more experiments performed in duplicate.
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displayed 11- and 16-fold activity over pGL3-Basic, respec-
tively (Fig. 3, right). Surprisingly, however, reporter constructs
corresponding to exons 1a and 1b were equally active or even
more active (Fig. 3, right) although these exons were expressed
at only very low levels in skeletal muscle (Fig. 1). Promoter
constructs corresponding to other exons (1h, 1j, and 1k) showed
some activity (Fig. 3, right), although these exons were
expressed at only very low levels in tibialis muscle.
In all three cell types (A673, SK-NM-C, and HaCaT cells)
the more active NOS1 promoters were stronger than the
moderately active SV40 promoter. The vector pGL3-Promot-
er (containing the SV40 promoter) showed 8.24 ± 0.65-fold
the activity of pGL3-Basic in A673 cells, 3.24 ± 0.2-
fold the activity of pGL3-Basic in SK-N-MC cells, 4.48 ± 0.31-
fold the activity of pGL3-Basic in HaCaT cells, and
56.64 ± 10.04-fold the activity of pGL3-Basic in C2C12
cells. However, none of the NOS1 promoters reached the
strength of the vector pGL3-Control (containing the SV40
promoter/enhancer). pGL3-Control showed 163.84 ± 11.25-
fold the activity of pGL3-Basic in A673 cells, 55.56 ± 7.73-
fold the activity of pGL3-Basic in SK-N-MC cells,
58.25 ± 12.91-fold the activity of pGL3-Basic in HaCaT
cells, and 132.18 ± 22.04-fold the activity of pGL3-Basic in
C2C12 cells.
Cell-type-specific stimulation of exon 1f and exon 1g promoter
activities
We have recently demonstrated in neuronal- and keratino-
cyte-like cells [6] that human NOS1 expression is increased
upon stimulation with various cAMP-activating agents. This is
due to increased transcriptional usage of exon 1f and/or 1g.
Interestingly, in the rat, stimulation of NOS1 expression in
pituitary gonadotrope cells was found to rely on a CRE site
located closely upstream of exon 1p homologous to exon 1f in
human NOS1 [10]. Since computational analyses (Fig. 4)
showed a conservation of this CRE site in humans, we tested its
functional relevance in human cells. We assessed the relative
activities of test constructs containing the exon 1f/1g promoter
region upon treatment with the protein kinase A-activating
compound dibutyryl-cAMP (db-cAMP). In SK-N-MC cells,
both the exon 1f full-length and the corresponding truncated
reporter construct (which still harbors the putative CRE site,
Figs. 4 and 5) showed an increase in reporter activity upon
stimulation. The same extent of stimulation was obtained with
the full-length exon 1g-related promoter containing the CRE
site (Fig. 5). However, the respective 5′–3′-deletion construct
lacking the CRE site (Figs. 4 and 5) showed decreased basal
activity and was not stimulated by db-cAMP.
These findings indicate a functional role for the conserved
CRE site located upstream of exon 1f in mediating inducibility
of NOS1 expression by db-cAMP.
Taken together, we have demonstrated that expression of 11
of the 12 described exon 1 variants of the human NOS1 gene is
facilitated by exon-specific promoters. Moreover, the overall
pattern of cell-type-specific promoter activities was in broadagreement with the expression profile of the endogenous exon 1
species in the respective cells.
Discussion
In this study, we have analyzed the cell-type-specific
expression pattern of the multiple exon 1 variants of the
human NOS1 gene. For 11 of the 12 described NOS1 exon 1
variants we have demonstrated that expression was facilitated
by individual exon-flanking promoters. Our data confirm
previous results, which demonstrated cell-type-specific usage
of a total of 12 different NOS1 exon 1 variants [6,11] and the
predominant expression of exons 1d, 1f, and 1g in various cell
types [6]. To our knowledge, the human NOS1 gene displays the
highest number of alternative promoters described so far. In
many cases, the activity of the exon 1-specific promoters
470 M. Bros et al. / Genomics 87 (2006) 463–473corresponded to the endogenous expression level of the
respective exon 1 variant.
The multiple exon 1 sequences of the human NOS1 gene
(1a–1l) are scattered over approximately 50 kb of genomic
region [6] with exons 1b to 1d and exons 1f to 1k clustered
within a short range. Notably, in mouse and rat, only three [12]
and six [10,13] alternative NOS1 exon 1 variants, respectively,
have been characterized so far. Exons 1f and 1g are the only
variants conserved between human and rodents (in mouse
designated exons 1a and 1b, in rat exons 1a and 1p). Whereas in
humans, both exons are separated by about 300 bp, they are
merged in rodents [10,12,14]. Exons 1f and 1g were also the
first NOS1 exon 1 variants described in humans, and the
corresponding 5′ flanking genomic regions were previously
shown to exert promoter activity [14]. While the promoter of
exon 1f could be stimulated by nerve growth factor [15],
activity of a promoter construct encompassing also the core
promoter region of exon 1g was enhanced by phorbol myristate
acetate [16]. In humans, other than the dual promoter region of
exons 1f and 1g, only the promoter of exon 1d, which is highly
expressed in brain, skin, heart, and skeletal muscle (Fig. 1), has
been analyzed in detail [17]. In patients with infantile
hypertrophic pyloric stenosis, NOS1 expression is strongly
decreased in pyloric tissue due to downregulated transcriptional
activity of exon 1d, which is the result of distinct promoter
polymorphisms in some cases [18]. In these patients, a
compensatory upregulation of exon 1f transcription was noted.
We have previously shown that stimulation of CREB
activity results in increased NOS1 expression as a consequence
of enhanced transcription of exons 1f/1g [6]. This is likely to
be mediated by a CRE binding site located immediately
upstream of exon 1f (see Fig. 5). Among the numerous stimuli
known to affect NOS1 expression, steroid hormones were
found to upregulate NOS1 in several cell types [19], while
corticosteroids decreased NOS1 expression [20]. In response to
lipopolysaccharide, which induces expression of proinflamma-
tory cytokines, and upon direct application of IFN-γ, NOS1
expression was either up- or downregulated in a cell-type-
specific manner [19,21]. However, the molecular basis for the
regulation of the NOS1 gene by these agents has been scarcely
analyzed and may involve both transcriptional and posttran-
scriptional mechanisms. For example, we have recently
demonstrated that NOS1 expression in keratinocytes was
increased upon stimulation with epidermal growth factor
(EGF) and contributed to keratinocyte proliferation. EGF
enhanced the level of exon 1i + 1k NOS1 mRNA due to
increased mRNA stability [6,8]. Moreover, Wang et al. [5]
have demonstrated that the different NOS1 exon 1 variants
exert cell-type-dependent differential translational efficiency.
Inclusion of exon 1k into NOS1 mRNA reduced in most cases
the rate of translation, forming a stem–loop structure, which
interacts with an RNA binding protein complex [22].
Taken together, the human NOS1 gene is highly complex in
terms of expressional regulation given the high number of 11
identified promoter regions and posttranscriptional mechan-
isms affecting mRNA stability and/or translational efficacy of
the various noncoding NOS1 exon 1 variants. All of thesemechanisms may interact to ensure a fine-tuned expressional
control of NOS1 in various cell types under normal and
stimulated conditions. Although most genes are controlled in
expression by a single promoter and harbor only one exon 1, a
survey of the human genome has revealed around 3000 genes
with more than one exon 1. Most of these genes (79%) contain
two different exon 1 variants [23]. Among them are the human
growth hormone receptor gene comprising a total of nine
different untranslated exon 1 variants [24] and the human
nuclear respiratory factor 1 gene, which exhibits at least six
different noncoding alternative exon 1 variants characterized
by differential translational efficiency [25].
Dysregulated NOS1 expression has been implicated in the
pathogenesis of neurodegenerative disorders such as stroke
[26], Parkinson disease [27], Alzheimer disease [28], and
amyotrophic lateral sclerosis [29]. Excessive formation of NO
and its metabolite peroxynitrite may be neurotoxic [30]. But
under distinct conditions of cellular stress, NO was shown to
exert neuroprotective effects [31]. In neuronal cells, NOS1
expression is enhanced under conditions of cellular stress and
injury and is linked to the activity of neurotransmitters [7,19].
Given the important role of NOS1 in both physiologic and
pathophysiologic conditions, our findings allow us to elucidate
which exon 1-flanking promoters are involved in NOS1
regulation in a given cell type and which pharmacological
agents may affect distinct NOS1 promoters to influence overall
NOS1 expression clinically.
Materials and methods
Human tissues
Human biopsies were obtained from the hospitals of the Johannes Gutenberg
University, Mainz, Germany, and the Albert Ludwig University, Freiburg,
Germany, according to the guidelines of the Human Ethical Committees of the
two universities. Tissue samples were either processed immediately or frozen in
dry ice and stored at −70°C.
Cell lines
The human neuroepithelial cell line A673, the human neuroblastoma cell
line SK-N-MC, the human keratinocyte cell line HaCaT [32], and the murine
myoblast cell line C2C12 were grown in Dulbecco's modified Eagle's medium
(DMEM; Invitrogen, Groningen, The Netherlands) supplemented with 10% of
fetal calf serum, 2 mM L-glutamine, and 100 U/ml penicillin/streptomycin
(PAA, Pasching, Austria). Cells were maintained in a 10% CO2 incubator at
37°C.
Quantification of the various first exon NOS1 mRNAs by RT real-time
PCR
Quantification of the distinct first exon NOS1 messages was obtained by
two-step RT real-time PCR using the iCyler (Bio-Rad, Munich, Germany). Total
RNA (10 to 25 μg), isolated from human biopsies or cell lines, was reverse
transcribed with the Omniscript RT kit (Invitrogen). An NOS1-specific antisense
primer was used to prime the reverse transcription (NOS1 RT, exons 5 and 6, 5′-
GGAGCCAAATCTTTTAATTGATGA-3′; GenBank, NM_000620: 1822–
1799). PCR were performed on 1/25 aliquots of the RT reaction with the
QuantiTect Probe PCR kit (Qiagen, Hilden, Germany) as recommended by the
manufacturer. For the detection of the various NOS1 transcripts, oligonucleo-
tides specific for each first exon were used as sense primers (Table 1); an exon 2
Table 1
Specific first exon sense primers used for RT real-time PCR
Name Sequence
NOS1a S 5′-CCCCTCCCTTGAGGAGCT-3′
NOS1b S 5′-CCCATGCTCTAGCTTGGAGC-3′
NOS1d S 5′-ATGCCAGGGTGAGGCCTT-3′
NOS1e S 5′-CTAAGAAGAAGGAGGAGGAGGAA-3′
NOS1f S 5′-CCGAGCGGACGGGCTC-3′
NOS1g S 5′-TGCCCGGCTCGGCGT-3′
NOS1g2 S 5′-CGGCTCGGCGTCAGCTC-3′
NOS1gk S 5′-GGCTCGGCGTCAGGTTG-3′
NOS1i S 5′-CCCCTGGGTTCTGGTCCTA-3′
NOS1i2 S 5′-TGTTGCGTGACCTTCGCT-3′
NOS1ik S 5′-TTGCGTGACCTTCGGTTG-3′
NOS1jk S 5′-GGAGCCTCTTAACTTTCAGGTTG-3′
NOS1k S 5′-AGCCATAGTCACCTAGCTGCTC-3′
NOS1L2 S 5′-AGACTTCAAGATGATCGTGCAAA-3′
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primer; and 5′-6FAM-TTCATTGCCAGCCTGTTAGATGCGGAT-TAMRA
was used as the fluorescent TaqMan probe. PCR conditions were initial
activation of the polymerase at 95°C for 15 min and 45 cycles of denaturation at
95°C for 15 s and annealing/extension at 60°C for 1 min. Fluorescence was
monitored at each cycle during the annealing/extension step.
Isolation and subcloning of the human NOS1 promoter regions
We obtained two PAC clones from the Ressourcenzentrum/Primärdatenbank
of the German Human Genome Project at the Max-Planck Institute for
Molecular Genetics (Berlin, Germany), which encompass adjacent genomic
regions of the NOS1 gene locus on chromosome 12q24.2–q24.3. They
respectively harbor exons 1a–1e (RP11-227B21) and exons 1f–1l (RP11-
33101) and the respective 5′ flanking genomic regions. For both PAC clones, the
genomic sequence had been determined (GenBank Accession Nos. AC073864
and AC068799).
As outlined in Fig. 2A, the multiple NOS1 exon 1 variants are located within
about 45 kb of the genomic sequence. Notably, both skeletal muscle-specific
exons 1b–1d and neuronal-specific exons 1f–1k form two clusters, with single
exons separated by a few hundred base pairs in many cases [6].
PAC clone DNA was digested with restriction enzymes PstI, SmaI
(RP11-227B21), and Acc65I (RP11-227B21, RP11-33101) in parallel
reactions. Restriction fragments were cloned into appropriately linearized
pZero-2.1 (Invitrogen). Transformants were used to generate colony filters in
duplicate. To generate exon 1-specific hybridization probes, 5′-RACE clones
that harbored exons 1a, 1d, 1e, 1f, and 1l were used as templates for PCR.
Exon sequences were amplified by using an appropriate exon 1 sense and
exon 2 antisense primer [6]. PCR products were labeled by incorporation of
digoxigenin-11–dUTP (Roche Diagnostics, Mannheim, Germany). Probe-
specific colonies were identified by colony filter hybridization as recommended
by the manufacturer.
Construction of promoter reporter constructs
To generate promoter construct Pex1a-7.1, an isolated 9.4-kb PstI fragment
was digested with ApaLI, which cuts at +116 bp relative to the transcription start
point, and 5′ overhangs were filled in using the Klenow enzyme. A 7.1-kb
promoter fragment was excised by a sequential digest with Acc65I that cuts
adjacent to the 5′-fragment end within the pZero2.1 polylinker. Promoterless
Photinus luciferase reporter vector pGL3-Basic (Promega, Heidelberg,
Germany) was double-digested with Acc65I and SmaI and ligated with the
exon 1a promoter fragment. To obtain a promoter construct for exon 1b, an
isolated 5.9-kb SmaI fragment was digested with Ecl136II, which excised a 785-
bp fragment, including 72 bp of exon 1b and 5′ flanking sequence. This Ecl136II
fragment was cloned into SmaI-linearized pGL3-Basic, thereby obtaining
Pex1b-0.79. Afterward, the 5.9-kb SmaI fragment was double-digested with
Acc65I (see above) and ScaI, which cuts 539 bp upstream of exon 1b. To obtainPex1b-5.03, this fragment was ligated with Pex1b-0.79 digested likewise. An
isolated 2.9-kb Acc65I PAC restriction fragment, encompassing exons 1c and
1d, was double-digested with Acc65I and StuI, which cuts within exon 1d at +96
bp, and cloned into Acc65I/SmaI double-digested pGL3-Basic (Pex1d-2.0). This
construct was double-digested with BstAPI, which cuts within exon 1c, and
BglII, which cuts within the downstream pGL3-Basic polylinker. Restriction site
overhangs were polished by treatment with mung bean nuclease and religated,
thereby generating Pex1c-1.65, which included 29 bp of exon 1c. Reporter
constructs Pex1c-1.65, Pex1d-2.0, and the 5.9-kb SmaI fragment were digested
with Acc65I (see above). The excised exon 1c/1d 5′ flanking region derived
from the SmaI PAC subclone was ligated with both of the precut luciferase
reporter constructs, thereby generating Pex1c-6.9 and Pex1d-7.27. Due to great
difficulties in cloning a PAC clone restriction fragment spanning exon 1e, we
switched to a PCR-based approach. By using PAC clone RP11-227B21 as
template, proofreading Pwo DNA polymerase, and primers 1e-sense (5′-
TGTATTTCAAAATAGCTAGAAGAGAGGAAT-3′) and 1e-antisense (5′-
CACAATGGGCATTTGCCTAACAAAATA-3′), we amplified a 2.57-kb
fragment that spans 2 kb of the exon 1e 5′ flanking region and exon 1e.
However, we were not successful in cloning this PCR product. We subcloned a
439-bp fragment, obtained by NheI/BamHI double-digest of the 2.57-kb PCR
product, that includes 8 bp of exon 1e (Pex1e-0.44). An isolated 9-kb Acc65I
fragment harboring exons 1f–1k was digested with EagI (+126 bp of exon 1f),
AccI (+42 bp of exon 1h), BsaI (+64 bp of exon 1j), and EcoRI (+19 bp of exon
1k), and 5′ overhangs were filled in by treatment with Klenow enzyme. The
respective promoter fragments were excised by Acc65I digestion and were
subcloned into pGL3-Basic, double-digested with Acc65I and SmaI. Thereby,
we generated Pex1f-6.53, Pex1h-7.13, Pex1j-8.97, and Pex1k-9.02. To obtain a
promoter construct for exon 1g, the 9-kb Acc65I fragment was digested with
FspI, and a resulting 1.47-kb fragment, cutting at +21 within exon 1g, was
subcloned into SmaI-linearized pGL3-Basic. This construct and the 9-kb Acc65I
fragment were double-digested with Acc65I and NdeI, which cuts 1.2 kb
upstream of exon 1g. The excised region was ligated with the proximal putative
promoter region of exon 1g, thereby generating Pex1g-6.91. Pex1i-7.88 was
obtained by digesting the 9-kb Acc65I fragment with Acc65I and XbaI, as the
latter cuts at +59 bp within exon 1i, and the excised promoter fragment was
ligated with Acc65I/NheI double-digested pGL3-Basic. To obtain a promoter
construct for exon 1l, an isolated 15.8-kb Acc65I fragment was used as template
for PCR. By employing proofreading Pwo DNA polymerase, vector-specific
M13 reverse primer (5′-CAGGAAACAGCTATGAC-3′), and an exon 1l-
specific antisense primer (5′-TCTACTGAGAGTGACGCAGCA-3′), a 1.83-kb
PCR product was generated that included 71 bp of exon 1l. This PCR product
was digested with Acc65I and cloned into Acc65I/SmaI double-digested pGL3-
Basic. The sizes and locations of the generated NOS1 promoter constructs are
depicted in Fig. 2B.
We also generated a series of 5′–3′-deletion constructs for the different exon
1 variants, which are depicted in Fig. 2B. The reporter constructs Pex1b-0.79
and Pex1c-1.65 had been obtained as by-products in the course of generating the
set of NOS1 promoter constructs (see above). To generate the other deletion
promoter constructs, the respective parental promoter construct was double
digested with Acc65I, which cuts at the 5′ end in all cases. The linearized
reporter constructs were digested in addition with AflII (Pex1a-7.1), SmaI
(Pex1h-7.13), SpeI (Pex1k-9.02), BstAPI (Pex1d-7.27), SacII (Pex1i-7.88), and
Ecl136II (Pex1l-1.83). In the case of protruding 5′ overhangs, double-digested
reporter constructs were end-polished by treatment with Klenow enzyme and
religated, thereby generating Pex1h-0.26 and Pex1k-0.12. In the case of 3′
overhangs, respective reporter constructs were treated with mung bean nuclease
and religated, thereby obtaining Pex1d-0.37 and Pex1i-0.39. The parental
promoter constructs for exon 1f (NcoI), exon 1g (Ecl136II), and exon 1j
(Ecl136II) were digested with the restriction enzyme indicated. The excised
fragments that harbor the respective proximal promoter region were ligated with
likewise linearized pGL3-Basic, thereby generating Pex1f-0.37, Pex1g-0.46,
and Pex1j-1.13.
Transient transfection and luciferase assays
For transient transfection, cells were seeded in wells of a 24-well cluster
plate at a density of 5 × 105 cells per well. Cells were transfected on the
following day with 950 ng of the largest promoter test construct and equimolar
472 M. Bros et al. / Genomics 87 (2006) 463–473amounts of shorter test constructs. To correct for differences in transfection
efficiency, cells were cotransfected with 50 ng of a Renilla luciferase
expression vector driven by the human elongation factor 1α1 gene promoter
[33]. In experiments conducted to test for the stimulatory activity of
dibutyryl-cAMP (Sigma, Deisenhofen, Germany), pRL-SV40 (Promega)
served as an internal control for transfection efficiency. Degraded salmon
sperm DNA (Roche Diagnostics) was added as necessary to obtain a total of
1 μg of DNA. The DNA mixture was incubated with 1.5 μl (A673, SK-N-
MC) or 1 μl (HaCaT, C2C12) of liposomal transfection reagent Fugene 6
(Roche Diagnostics). Test constructs were tested in duplicate in at least three
independent experiments. Luciferase activities were measured 24 h after
transfection. Relative promoter activities were determined as the ratio of
Photinus and Renilla luciferase activity.
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